Science

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck

Nerviano Medical Sciences announced an agreement with Merck under which the two companies will collaborate on the discovery of small molecule inhibitors of certain molecular targets in the area of DNA damage repair.
( PR4US.com | Press Release | 2018-06-04 16:07:34 )
Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents.
Under the terms of the agreement, Nerviano Medical Sciences grants Merck an exclusive right to conduct joint research and to develop, manufacture and commercialize inhibitors of certain molecular targets in the area of DNA damage repair.

The collaboration between Nerviano Medical Sciences and Merck will initially focus on one target and shall encompass two stages. Nerviano Medical Sciences and Merck will first conduct research work in close collaboration with each other and Merck will subsequently further develop, manufacture and commercialize selected collaboration compounds.

Terms of the multiyear collaboration include an upfront fee in consideration of the rights and licenses granted by Nerviano Medical Sciences to Merck as well as partial funding of the costs incurred by Nerviano Medical Sciences for the conduct of the research program. As additional considerations, Merck shall pay research, development and commercial success milestones, as well as royalties on worldwide sales of products.

“This agreement between Merck and Nerviano Medical Sciences marks a new achievement in our collaboration strategy” - said Andrea Agazzi, Chairman of NMS Group. “We are very excited about the prospect of collaborating with Merck. We believe that by working together and applying our complementary world class research capabilities, we may be able to develop innovative and valuable products for the market.”

“We are thrilled at the prospect of joining forces with Merck in the discovery and development of innovative therapies in the field of defective DNA damage repair mechanisms, which both our teams view to be amongst the most important susceptibilities of cancer to be leveraged in the fight against this disease” - added Arturo Galvani, Head of Discovery Research at Nerviano Medical Sciences. “I believe that this partnership, which combines Nerviano’s expertise in the discovery and development of high-quality drug candidates with Merck’s scientific expertise as a global healthcare leader, is ideally configured for the task of delivering effective new therapies for the care of cancer patients.”

NMS Group S.p.A. and its companies

With more than 420 total employees, NMS Group is the largest company in Italy and one of the most representative in Europe committed in oncology innovation and R&D and it is able to manage the entire integrated chain of the R&D path.
Nerviano Medical Sciences is the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. NMS Group provides services of Research and Production, addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and NerPharMa, dealing with activities from formulation to production of the active principle.


Press Information

NMS Group - Nerviano Medical Sciences
Viale Pasteur, Nerviano (MI) IT

+390331581111

Contact person
Chiara Lattuada
Communication & Istitutional relations
www.nervianoms.com

eMail

Published by

Chiara Lattuada
http://www.nervianoms.com/en/

Contact Chiara Lattuada


 

 

 

 

 

 

Contact NMS Group - Nerviano Medical Sciences


 

 

 

 

 

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact PR4US. We will not be able to assist you. PR4US disclaims the content included in this release.
Preparing for PR: Five Hot Tips for Startups
PR Fundamentals for Startups - MaRS Best Practices
Public Relations 101
Public Relations Strategy in Our World Today!
Introduction to Public Relations
Trends in Communicating
How to Do Marketing/PR on a Budget - CoInvent Startup Summit 2014 New York
Monika Dixon Shares PR Tips